O6-Methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma

被引：28

作者：

Watanabe, Reiko ^{[1
]}

Nakasu, Yoko ^{[2
]}

Tashiro, Hiroshi ^{[1
]}

Mitsuya, Koichi ^{[2
]}

Ito, Ichiro ^{[1
]}

Nakasu, Satoshi ^{[3
]}

Nakajima, Takashi ^{[1
]}

机构：

[1] Shizuoka Canc Ctr, Div Diagnost Pathol, Shizuoka 4118777, Japan

[2] Shizuoka Canc Ctr, Div Neurosurg, Shizuoka 4118777, Japan

[3] Kusatsu Gen Hosp, Div Neurooncol, Shiga, Japan

来源：

BRAIN TUMOR PATHOLOGY | 2011年 / 28卷 / 02期

关键词：

Glioblastoma; Immunohistochemistry; MGMT; Temozolomide; MGMT PROMOTER METHYLATION; MALIGNANT GLIOMA; HYPERMETHYLATION; GENE; SURVIVAL; IMMUNOHISTOCHEMISTRY; ASTROCYTOMAS; COMPONENTS; REGIONS;

D O I：

10.1007/s10014-011-0022-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Expression of the O-6-methylguanine-DNA methyltransferase (MGMT) gene has been shown to correlate with clinical outcomes in patients with glioblastoma multiforme treated with alkylating agents. We evaluated MGMT protein expression in 53 primary glioblastomas by the immunohistochemistry (IHC) and analyzed the correlation between results of immunostaining and patient outcomes. There were 28 MGMT-immunopositive and 25 negative glioblastomas. Patients with MGMT-immunonegative glioblastomas showed significantly longer progression-free survival (PFS) (P = 0.0032), but no statistically significant benefits on overall survival (OS) (P = 0.0825) were shown. In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both PFS and OS were significantly better in MGMT-immunonegative glioblastomas. (PFS: P = 0.0015, OS: P = 0.0384). We conclude that MGMT expression on immunohistochemistry (IHC) correlates with outcomes in patients with primary glioblastoma receiving TMZ and suggest the use of MGMT-IHC as a surrogate marker for predicting tumor chemosensitivity.

引用

页码：127 / 135

页数：9

共 22 条

[1] Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas [J].

Brell, M ;

Tortosa, A ;

Verger, E ;

Gil, JM ;

Viñolas, N ;

Villá, S ;

Acebes, JJ ;

Caral, L ;

Pujol, T ;

Ferrer, I ;

Ribalta, T ;

Graus, F .

CLINICAL CANCER RESEARCH, 2005, 11 (14) :5167-5174

[2] Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach [J].

Capper, David ;

Mittelbronn, Michel ;

Meyermann, Richard ;

Schittenhelm, Jens .

ACTA NEUROPATHOLOGICA, 2008, 115 (02) :249-259

[3] Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide [J].

Chinot, Olivier L. ;

Barrie, Maryline ;

Fuentes, Stephane ;

Eudes, Nathalie ;

Lancelot, Sophie ;

Metellus, Philippe ;

Muracciole, Xavier ;

Braguer, Diane ;

Ouafik, L'Houcine ;

Martin, Pierre-Marie ;

Dufour, Henry ;

Figarella-Branger, Dominique .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1470-1475

[4]

Esteller M, 1999, CANCER RES, V59, P793

[5] Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas [J].

Everhard, Sibille ;

Tost, Joerg ;

El Abdalaoui, Hafida ;

Criniere, Emmanuelle ;

Busato, Florence ;

Marie, Yannick ;

Gut, Ivo G. ;

Sanson, Marc ;

Mokhtari, Karima ;

Laigle-Donadey, Florence ;

Hoang-Xuan, Khe ;

Delattre, Jean-Yves ;

Thillet, Joelle .

NEURO-ONCOLOGY, 2009, 11 (04) :348-356

[6] Clinical relevance of MGMT in the treatment of cancer [J].

Gerson, SL .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2388-2399

[7] Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas [J].

Grasbon-Frodl, Eva M. ;

Kreth, Friedrich Wilhelm ;

Ruiter, Michael ;

Schnell, Oliver ;

Bise, Karl ;

Felsberg, Joerg ;

Reifenberger, Guido ;

Tonn, Joerg-Christian ;

Kretzschmar, Hans A. .

INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (11) :2458-2464

[8] MGMT gene silencing and benefit from temozolomide in glioblastoma [J].

Hegi, ME ;

Diserens, A ;

Gorlia, T ;

Hamou, M ;

de Tribolet, N ;

Weller, M ;

Kros, JM ;

Hainfellner, JA ;

Mason, W ;

Mariani, L ;

Bromberg, JEC ;

Hau, P ;

Mirimanoff, RO ;

Cairncross, JG ;

Janzer, RC ;

Stupp, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003

[9] Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity [J].

Hegi, Monika E. ;

Liu, Lili ;

Herman, James G. ;

Stupp, Roger ;

Wick, Wolfgang ;

Weller, Michael ;

Mehta, Minesh P. ;

Gilbert, Mark R. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) :4189-4199

[10] MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas [J].

Jeuken, Judith Wm ;

Cornelissen, Sandra J. B. ;

Vriezen, Martine ;

Dekkers, Marieke M. G. ;

Errami, Abdellatif ;

Sijben, Angelique ;

Boots-Sprenger, Sandra H. E. ;

Wesseling, Pieter .

LABORATORY INVESTIGATION, 2007, 87 (10) :1055-1065

← 1 2 3 →